Abstract
BackgroundImmune checkpoint blockade (ICB) has revolutionized cancer immunotherapy. However, most patients with cancer fail to respond clinically. One potential reason is the accumulation of immunosuppressive transforming growth factor β (TGFβ)...
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have